See more : Hod Assaf Industries Ltd. (HOD.TA) Income Statement Analysis – Financial Results
Complete financial analysis of Spectrum Pharmaceuticals, Inc. (SPPI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Spectrum Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Netflix, Inc. (NFLX) Income Statement Analysis – Financial Results
- PT Citra Buana Prasida Tbk (CBPE.JK) Income Statement Analysis – Financial Results
- Ruida Futures Co., Ltd. (002961.SZ) Income Statement Analysis – Financial Results
- DraftKings Inc. (DKNG) Income Statement Analysis – Financial Results
- MedinCell S.A. (MEDCL.PA) Income Statement Analysis – Financial Results
Spectrum Pharmaceuticals, Inc. (SPPI)
About Spectrum Pharmaceuticals, Inc.
Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology and hematology drug products. The company's products under development include Eflapegrastim, a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia; Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations; and Anti-CD20-IFNa, an antibody-interferon fusion molecule directed against CD20 that is in Phase I development for the treatment of patients with relapsed or refractory non-Hodgkin's lymphoma, including diffuse large B-cell lymphoma. It has co-development, commercialization, and in-license agreements with Hanmi Pharmaceutical Co. Ltd.; a patent and technology license agreement with The University of Texas M.D. Anderson Cancer Center; and in-license agreement with ImmunGene, Inc. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was incorporated in 1987 and is based in Boston, Massachusetts.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 10.11M | 0.00 | 0.00 | 22.62M | 109.33M | 128.37M | 146.44M | 162.56M | 186.83M | 155.85M | 267.71M | 192.96M | 74.11M | 38.03M | 28.73M | 7.67M | 5.67M | 577.00K | 258.00K | 1.00M | 2.37M | 41.11K | 1.00 | 1.00 | 100.00K | 100.00K | 100.00K |
| Cost of Revenue | 1.79M | 0.00 | 0.00 | 12.01M | 26.76M | 47.22M | 35.84M | 27.69M | 27.04M | 28.58M | 46.63M | 33.84M | 17.44M | 8.15M | 1.19M | 0.00 | 97.00K | 397.00K | 123.00K | 0.00 | 0.00 | 0.00 | -1.13M | -519.88K | -500.00K | -200.00K | 0.00 |
| Gross Profit | 8.32M | 0.00 | 0.00 | 10.61M | 82.58M | 81.15M | 110.60M | 134.87M | 159.79M | 127.27M | 221.07M | 159.13M | 56.67M | 29.88M | 27.53M | 7.67M | 5.58M | 180.00K | 135.00K | 1.00M | 2.37M | 41.11K | 1.13M | 519.88K | 600.00K | 300.00K | 100.00K |
| Gross Profit Ratio | 82.28% | 0.00% | 0.00% | 46.91% | 75.53% | 63.22% | 75.52% | 82.97% | 85.53% | 81.66% | 82.58% | 82.46% | 76.47% | 78.57% | 95.85% | 100.00% | 98.29% | 31.20% | 52.33% | 100.00% | 100.00% | 100.00% | 112,813,400.00% | 51,987,600.00% | 600.00% | 300.00% | 100.00% |
| Research & Development | 42.20M | 87.30M | 109.38M | 79.33M | 94.96M | 65.90M | 58.94M | 50.77M | 69.66M | 46.67M | 42.54M | 27.72M | 57.30M | 21.06M | 26.68M | 33.29M | 17.87M | 12.60M | 6.95M | 3.68M | 12.73M | 20.61M | 38.77M | 20.06M | 8.50M | 4.50M | 600.00K |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 38.82M | 60.41M | 60.36M | 61.37M | 90.70M | 84.27M | 87.35M | 86.51M | 97.41M | 99.32M | 91.97M | 72.55M | 48.55M | 33.61M | 15.16M | 11.58M | 13.60M | 7.50M | 5.98M | 7.62M | 4.10M | 7.58M | 5.11M | 3.47M | 3.10M | 2.30M | 700.00K |
| Other Expenses | -5.33M | -10.89M | -2.94M | -8.89M | 9.58M | 389.00K | 887.00K | -1.25M | -4.37M | -722.00K | -844.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 81.02M | 147.70M | 169.73M | 140.70M | 213.75M | 177.81M | 172.23M | 175.60M | 191.36M | 166.06M | 141.25M | 103.99M | 109.57M | 58.39M | 42.00M | 44.87M | 31.47M | 20.10M | 12.94M | 11.31M | 16.83M | 28.19M | 45.00M | 24.04M | 12.10M | 7.00M | 1.30M |
| Cost & Expenses | 82.81M | 147.70M | 169.73M | 140.70M | 240.51M | 225.03M | 208.07M | 203.29M | 218.40M | 194.64M | 187.88M | 137.83M | 127.01M | 66.53M | 43.20M | 44.87M | 31.57M | 20.50M | 13.06M | 11.31M | 16.83M | 28.19M | 43.87M | 23.52M | 11.60M | 6.80M | 1.30M |
| Interest Income | 968.00K | 163.00K | 1.34M | 5.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.61M | 0.00 | 0.00 | 83.00K | 0.00 | 0.00 | 776.35K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 998.00K | 0.00 | 0.00 | -5.00M | 340.00K | 6.80M | 9.44M | 9.07M | 8.58M | 2.19M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 17.00K | 0.00 | 0.00 | 1.86M | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | -4.36M | 286.00K | 261.00K | 3.34M | 28.10M | 27.65M | 25.95M | 38.32M | 24.29M | 20.07M | 6.74M | 5.65M | 4.51M | 3.72M | 610.00K | 255.00K | 198.00K | 682.00K | 425.00K | 346.00K | 1.33M | 2.27M | 1.13M | 519.88K | 500.00K | 200.00K | -300.00K |
| EBITDA | -77.06M | -147.70M | -169.73M | -140.70M | -93.50M | -68.62M | -34.80M | -3.66M | -11.65M | -21.58M | 86.57M | 63.69M | -52.40M | -25.45M | -10.33M | -40.08M | -26.28M | -20.52M | -12.38M | -9.81M | -9.92M | -25.68M | -42.74M | -20.78M | -11.20M | -7.20M | -1.50M |
| EBITDA Ratio | -761.91% | 0.00% | 0.00% | -622.14% | -85.52% | -53.46% | -23.76% | -2.25% | -6.23% | -13.85% | 32.34% | 33.01% | -70.70% | -66.93% | -35.94% | -522.41% | -463.18% | -3,556.15% | -4,797.29% | -980.80% | -418.13% | -62,458.85% | -4,273,686,000.00% | -2,077,988,900.00% | -11,200.00% | -7,200.00% | -1,500.00% |
| Operating Income | -72.70M | -147.70M | -169.73M | -144.03M | -131.18M | -96.66M | -61.63M | -40.73M | -31.57M | -38.79M | 79.82M | 55.13M | -52.90M | -28.51M | -19.17M | -37.20M | -25.89M | -19.92M | -12.80M | -10.47M | -17.51M | -28.15M | -43.87M | -23.52M | -11.50M | -6.70M | -1.20M |
| Operating Income Ratio | -718.78% | 0.00% | 0.00% | -636.89% | -119.98% | -75.30% | -42.08% | -25.06% | -16.90% | -24.89% | 29.82% | 28.57% | -71.37% | -74.97% | -66.74% | -484.81% | -456.43% | -3,452.69% | -4,961.24% | -1,046.80% | -738.28% | -68,469.52% | -4,387,369,500.00% | -2,352,312,900.00% | -11,500.00% | -6,700.00% | -1,200.00% |
| Total Other Income/Expenses | -5.36M | -10.73M | -1.60M | 174.20M | 11.17M | -11.37M | -9.20M | -9.65M | -11.96M | 2.15M | -844.00K | -2.91M | 4.01M | 8.74M | 3.70M | 3.14M | 581.00K | 1.28M | 2.00K | 78.00K | -126.50M | -200.69K | -8.70K | -2.22M | 200.00K | 700.00K | 300.00K |
| Income Before Tax | -78.06M | -158.43M | -171.33M | -144.59M | -120.01M | -108.03M | -70.83M | -50.38M | -43.53M | -36.64M | 78.98M | 52.22M | -48.89M | -19.77M | -22.71M | -34.06M | -25.31M | -18.64M | -12.80M | -10.62M | -20.72M | -28.35M | -43.88M | -25.75M | -11.30M | -6.00M | -900.00K |
| Income Before Tax Ratio | -771.78% | 0.00% | 0.00% | -639.37% | -109.77% | -84.15% | -48.36% | -30.99% | -23.30% | -23.51% | 29.50% | 27.06% | -65.96% | -51.99% | -79.04% | -443.90% | -446.18% | -3,231.02% | -4,960.47% | -1,061.90% | -873.80% | -68,957.67% | -4,388,239,700.00% | -2,574,649,400.00% | -11,300.00% | -6,000.00% | -900.00% |
| Income Tax Expense | 46.00K | 4.00K | -60.00K | -9.21M | 1.00K | -16.78M | -2.31M | 406.00K | 2.19M | 25.50M | -15.57M | 3.70M | -43.00K | -421.00K | 997.00K | -3.16M | -2.61M | -1.28M | -514.00K | 85.00K | 3.18M | -315.05K | 2.55M | 2.47M | 100.00K | -500.00K | 100.00K |
| Net Income | -78.10M | -158.44M | -171.27M | -135.39M | -120.01M | -91.25M | -68.51M | -50.79M | -45.72M | -62.13M | 94.55M | 48.52M | -48.84M | -19.05M | -15.47M | -34.04M | -23.28M | -18.64M | -12.29M | -10.39M | -17.63M | -27.83M | -46.43M | -25.99M | -11.60M | -6.20M | -1.00M |
| Net Income Ratio | -772.24% | 0.00% | 0.00% | -598.66% | -109.77% | -71.08% | -46.78% | -31.24% | -24.47% | -39.87% | 35.32% | 25.14% | -65.90% | -50.09% | -53.85% | -443.64% | -410.44% | -3,230.85% | -4,762.02% | -1,039.00% | -743.61% | -67,703.21% | -4,642,728,700.00% | -2,598,990,500.00% | -11,600.00% | -6,200.00% | -1,000.00% |
| EPS | -0.43 | -1.02 | -1.38 | -1.22 | -1.16 | -1.07 | -0.94 | -0.78 | -0.71 | -1.02 | 1.61 | 0.94 | -0.99 | -0.48 | -0.49 | -1.17 | -0.96 | -1.06 | -0.97 | -2.49 | -12.34 | -40.42 | -122.82 | -91.45 | -51.64 | -716.85 | -7.41 |
| EPS Diluted | -0.43 | -1.02 | -1.38 | -1.22 | -1.16 | -1.07 | -0.94 | -0.78 | -0.71 | -1.02 | 1.46 | 0.86 | -0.99 | -0.48 | -0.49 | -1.17 | -0.96 | -1.06 | -0.97 | -2.49 | -12.34 | -40.42 | -122.82 | -91.45 | -51.64 | -716.85 | -7.41 |
| Weighted Avg Shares Out | 183.24M | 154.86M | 124.39M | 110.59M | 103.31M | 85.12M | 72.82M | 64.88M | 64.71M | 60.73M | 58.59M | 53.27M | 49.50M | 39.27M | 31.55M | 29.01M | 24.31M | 17.66M | 12.67M | 4.17M | 1.43M | 688.62K | 378.02K | 284.20K | 224.62K | 8.65K | 134.98K |
| Weighted Avg Shares Out (Dil) | 183.24M | 154.86M | 124.39M | 110.59M | 103.31M | 85.12M | 72.82M | 64.88M | 64.71M | 60.73M | 64.64M | 57.96M | 49.50M | 39.27M | 31.55M | 29.01M | 24.31M | 17.66M | 12.67M | 4.17M | 1.43M | 688.62K | 378.02K | 284.20K | 224.62K | 8.65K | 134.98K |
Qylur Awarded SBIR Phase II Contract for a Tactical AI Spectrum Classifier Systems (TASCS)
Qylur's SNIM® AI and Autonomous Systems capabilities to address key challenge for Agile Spectrum Superiority Qylur's SNIM® AI and Autonomous Systems capabilities to address key challenge for Agile Spectrum Superiority
Qylur Awarded SBIR Phase II Contract for Tactical AI Spectrum Classifier Systems (TASCS)
Qylur's SNIM® AI and Autonomous Systems capabilities to address key challenge for Agile Spectrum Superiority Qylur's SNIM® AI and Autonomous Systems capabilities to address key challenge for Agile Spectrum Superiority
NanoViricides prepares for Phase II trial of broad-spectrum antiviral NV-387
NanoViricides (NYSE-A:NNVC) is advancing its clinical program with plans for an innovative Phase II trial of its drug candidate NV-387, the company announced Monday. The drug candidate NV-387, which has shown promise in treating various viral infections including RSV, COVID-19,...
STALICLA publishes pioneering phase 1b data on precision treatment for autism spectrum disorder in Biomedicines
Press Release STALICLA's precision psychiatry study highlights strong EEG-based target engagement of STP1 treatment in defined subgroup of patients with autism and numerical improvement in core symptoms Geneva, Switzerland – June 27, 2024 – STALICLA SA, a Swiss neuro precision...
Osivax Completes Enrollment for Phase 1 Trial with Broad-Spectrum Sarbecovirus Vaccine Candidate, OVX033
LYON, France--(BUSINESS WIRE)--Osivax, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating respiratory viruses, today announced that it has completed enrollment in its Phase 1 trial (NCT06128382) with OVX033, the company's broad-spectrum vaccine candidate against sarbecoviruses. The...
Pneumagen Presents Positive Phase 2 Influenza Human Challenge Study data on Neumifil, its Broad-Spectrum Antiviral Drug, at the American Thoracic Society (ATS) 2024 Conference
St Andrews, UK – 23nd May 2024 - Pneumagen, a clinical stage biotech company developing Neumifil (HEX17), a broad-spectrum antiviral, intranasal drug for the prophylaxis and treatment of viral respiratory tract infections (RTIs), presented positive results from its Phase 2,...
Pneumagen to Present Phase 2 Clinical Data on Neumifil, its Broad-Spectrum Antiviral, Intranasal Drug for Viral Respiratory Tract Infections, at ATS 2024
Data to be presented in oral and ePoster presentations St Andrews, UK – 2 May 2024 - Pneumagen, a clinical stage biotech company developing Neumifil, a broad-spectrum antiviral, intranasal drug for the prophylaxis and treatment of viral respiratory tract infections...
NanoViricides completes Phase 1a/1b human clinical trial for its broad-spectrum antiviral drug
NanoViricides (NYSE-A:NNVC) has successfully wrapped up the first phase of a human clinical trial for its broad-spectrum antiviral drug, NV-CoV-2. The company said that the drug was well-tolerated, with no adverse events reported in any of the three dose levels...
Basilea announces acquisition of fosmanogepix, a phase-3-ready broad-spectrum antifungal
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, November 13, 2023 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that it...
Pneumagen Announces Successful Clinical Proof of Concept for its Broad-Spectrum Antiviral Neumifil in Phase 2 Influenza Human Challenge Study
St Andrews, UK – 2nd October 2023 - Pneumagen, a clinical stage biotech company developing Neumifil, a broad-spectrum antiviral, intranasal drug for the prophylaxis and treatment of viral respiratory tract infections (RTIs), today announced positive results from its Phase 2,...
Source: https://incomestatements.info
Category: Stock Reports